# Codex Review: medical_monitoring_phase_b5_mapping_approval_gate_20260801

Date: 2026-08-01 23:39 CST
Execution: Codex direct; no Hermes route, conference, or sub-agent was used.
Changed source/test/evidence:
- `services/api/app/medical_risk_mapping_approval.py`
- `tests/test_medical_risk_mapping_approval.py`
- `runs/execution/medical_monitoring_phase_b5_mapping_approval_gate_20260801/APPROVAL_GATE_ASSERTIONS.json`

## Verdict

**Pass for the explicit approval-gate contract; actual clone candidates correctly fail the gate because no independent approvals exist.**

## Boundary Check

- The gate is pure and non-writing; only deep-copy dry-run records can be returned.
- No actual candidate was marked approved; no runtime database, schema, service, router,
  frontend, medical-writing path or frozen job was changed.
- 8911/5174 remain stopped and 18911 was not touched.

## Codex Verification

- B5 focused approval-gate tests: **4 passed**.
- Combined B1-B5 + existing risk compatibility set: **112 passed, 17 warnings**.
- pycompile and Ruff check for approval source/test and actual-candidate assertion script: passed.
- Actual A6 clone assertion:
  `runs/execution/medical_monitoring_phase_b5_mapping_approval_gate_20260801/APPROVAL_GATE_ASSERTIONS.json`
  reports 5 candidates, all `approved=false`, all `write_permitted=false`, all
  `review_required=true`, `gate_passed=false` because independent approval evidence is absent.
- Synthetic approved input tests prove candidate fingerprint binding, reviewer/source
  evidence requirements, rejected/residual-blocked fail-closed behavior, record-id
  binding and deep-copy non-write behavior.

## Direct Work Review

- Approval evidence is hash-bound to candidate identity fields and cannot be reused after
  a current instance/key/source change.
- Approving a candidate does not permit runtime writes; it only enables a controlled
  in-memory remap. Actual migration requires a separate authority/rollback gate.
- The real clone has no synthetic approval record; no decision was fabricated.

## Residual Risk

- The five actual candidates still require explicit medical/engineering review and the
  MY009 source-lineage/event-replay blockers remain unresolved.
- Runtime migration, restart/rollback, permissions, dual-read parity and UI integration
  remain pending; this gate does not close Phase B or the project Goal.
